{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:59Z","timestamp":1753891979495,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T00:00:00Z","timestamp":1528761600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF15SA0018404"],"award-info":[{"award-number":["NNF15SA0018404"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00611","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T12:29:50Z","timestamp":1528806590000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Pillars and Pitfalls of the New Pharmacovigilance Legislation: Consequences for the Identification of Adverse Drug Reactions Deriving From Abuse, Misuse, Overdose, Occupational Exposure, and Medication Errors"],"prefix":"10.3389","volume":"9","author":[{"given":"Maurizio","family":"Sessa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"di Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Mascolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Rafaniello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liberata","family":"Sportiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Scavone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA \u2013 Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS ONE"},{"key":"B2","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/15563650802559632","article-title":"2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report","volume":"46","author":"Bronstein","year":"2008","journal-title":"Clin. Toxicol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1526-4637.2006.00259.x","article-title":"The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS)","volume":"8","author":"Cicero","year":"2007","journal-title":"Pain Med"},{"key":"B4","unstructured":"Guideline on Good Pharmacovigilance Practices (GVP). United Kingdom, EMA\/876333\/2017"},{"key":"B5","unstructured":"Directive 2010\/84\/EU. 25"},{"key":"B6","doi-asserted-by":"crossref","unstructured":"Regulation 1235\/2010. 16","DOI":"10.2174\/138161210790945904"},{"key":"B7","unstructured":"Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting E2D2018"},{"key":"B8","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/AJP.0b013e318125c5e8","article-title":"Challenges in the development of prescription opioid abuse-deterrent formulations","volume":"23","author":"Katz","year":"2007","journal-title":"Clin. J. Pain"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/2050-6511-14-8","article-title":"Unusual case of severe arrhythmia developed after acute intoxication with tosylchloramide","volume":"14","author":"Lariccia","year":"2013","journal-title":"BMC Pharmacol. Toxicol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/14740338.2017.1316486","article-title":"Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation","volume":"16","author":"Leporini","year":"2017","journal-title":"Expert Opin. Drug Saf"},{"key":"B11","first-page":"2121","article-title":"Addiction: Part I. Benzodiazepines\u2013side effects, abuse risk and alternatives","volume":"61","author":"Longo","year":"2000","journal-title":"Am. Fam. Physician"},{"key":"B12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40264-016-0399-8","article-title":"Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis\/Arthralgia: a review of clinical cases","volume":"39","author":"Mascolo","year":"2016","journal-title":"Drug Saf"},{"key":"B13","first-page":"407","article-title":"Self-harm and suicide associated with benzodiazepine usage","volume":"57","author":"Neale","year":"2007","journal-title":"Br. J. Gen. Pract"},{"key":"B14","first-page":"28","article-title":"Benzodiazepine use, abuse, and dependence","volume":"66","author":"O'brien","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1517\/14740338.2014.939582","article-title":"Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy","volume":"13","author":"Parretta","year":"2014","journal-title":"Expert Opin. Drug Saf"},{"key":"B16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.phrs.2015.12.026","article-title":"Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: results of a pharmacovigilance reporting system","volume":"104","author":"Rafaniello","year":"2016","journal-title":"Pharmacol. Res"},{"volume-title":"Pathogenesis of Adverse Drug Reactions.","year":"1977","author":"Rawlins","key":"B17"},{"key":"B18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jama.1988.03720040047025","article-title":"Clarification and standardization of substance abuse terminology","volume":"259","author":"Rinaldi","year":"1988","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40264-017-0530-5","article-title":"The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: a retrospective comparative analysis","volume":"40","author":"Rolfes","year":"2017","journal-title":"Drug Saf"},{"key":"B20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0160337","DOI":"10.1371\/journal.pone.0160337","article-title":"Effect of chronic kidney diseases on mortality among digoxin users treated for non-valvular atrial fibrillation: a nationwide register-based retrospective cohort study","volume":"11","author":"Sessa","year":"","journal-title":"PLoS ONE"},{"key":"B22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/tpj.2017.38","article-title":"The predictive value of ABCB1, ABCG2, CYP3A4\/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions","volume":"18","author":"Sessa","year":"","journal-title":"Pharmacogenomics J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14740338.2016.1221397","article-title":"Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs","volume":"15","author":"Sessa","year":"","journal-title":"Expert Opin. Drug Saf"},{"key":"B24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14740338.2016.1226280","article-title":"Campania preventability assessment committee: a focus on the preventability of the contrast media adverse events","volume":"15","author":"Sessa","year":"","journal-title":"Expert Opin. Drug Saf."},{"key":"B25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3389\/fphar.2017.00305","article-title":"Campania Preventability Assessment Committee (Italy): a focus on the preventability of non-steroidal anti-inflammatory drugs' adverse drug reactions","volume":"8","author":"Sessa","year":"","journal-title":"Front. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4103\/0976-500X.184777","article-title":"A case of figurate urticaria by etanercept","volume":"7","author":"Sessa","year":"","journal-title":"J. Pharmacol. Pharmacother"},{"article-title":"Appendix A: Description of the survey","volume-title":"Summary of findings from the 2000 National Household Survey on Drug Abuse (NHSDA Series H-13, DHHS Publication No. [SMA] 01-3549, pp. 63-68)","year":"2001","key":"B27"},{"key":"B28","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/pds.3556","article-title":"The upper bound to the relative reporting ratio-a measure of the impact of the violation of hidden assumptions underlying some disproportionality methods used in signal detection","volume":"23","author":"Van Holle","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf"},{"key":"B29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1046\/j.1365-2125.2003.01968.x","article-title":"Application of data mining techniques in pharmacovigilance","volume":"57","author":"Wilson","year":"2004","journal-title":"Br. J. Clin. Pharmacol"},{"volume-title":"Lexicon of Alcohol and Drug Terms","year":"1994","key":"B30"},{"key":"B31","first-page":"28","article-title":"WHO launches pharmacovigilance toolkit","volume":"1386","year":"2012","journal-title":"Reactions"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00611\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T10:14:12Z","timestamp":1571480052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00611\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,12]]},"references-count":31,"alternative-id":["10.3389\/fphar.2018.00611"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00611","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2018,6,12]]},"article-number":"611"}}